Efficacy and Safety of Darolutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer Stratified by PSA Doubling Time
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
European Urology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial
Eur Urol 2022 Sep 08;[EPub Ahead of Print], M Bögemann, ND Shore, MR Smith, TLJ Tammela, A Ulys, E Vjaters, S Polyakov, M Jievaltas, M Luz, B Alekseev, T Lebret, M Schostak, F Verholen, MA Le Berre, S Srinivasan, J Ortiz, AF Mohamed, T Sarapohja, K FizaziFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Advanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.